Hypertension: The Cardiovascular Risk Continuum by Wita, IW
S5  
Acta Cardiologia Indonesiana (Vol. 3 No. 1) 2017 [supplement]: S5
Symposium II. Prevention in Hypertension
Hypertension: The Cardiovascular Risk Continuum
Wita IW*
Department of Cardiology and Vascular Medicine Medical Faculty of
Udayana University - Sanglah Hospital Denpasar, Bali, Indonesia
*corresponding author: kardiologibali@gmail.com
Abstract
Hypertension is established modifi able risk factor for cardiovascular diseases (CVD) and should 
be considered a complex cardiovascular disorder and  continues to be a topic of interest.Together 
with dyslipidemia, diabetes mellitus and cigarette smoking and all of them, along with nonmodifi able 
risk factors, age, gender and family history of CVD, have been incorporated into algorithm for 
risk assessment in the general population. Pathological sequence of events leading from risk 
factors to CVD is called The Cardiovascular continuum. CVD are the most importantcause of 
death in the Western world and are responsible fora large proportion of the overall mortality and 
morbiditycurrently observed in the population of the developedcountries. Atherosclerosis is the 
main cause of CVDand is the fi nal result of a chain of events leading from riskfactors to overt CV 
complications including catastrophicevents such as stroke, myocardial infarction, or sudden death.  
A cumulative analysis of over250,000 adults enrolled from 18 different cohort studiesand followed 
up for three decades showed that the lifetime risk for developing a symptomatic CVD increased
progressively over time in both sexes with a direct relationship with the individual number 
of CV risk factors and theextent of their control according to guidelines. This suggests the 
importance of a reliable assessment of the CVrisk profi le for a preventive strategy of CV 
complications.However, despite the advancement in the knowledge ofthe epidemiology and 
pathophysiology of atheroscleroticvascular disorders, the burden of CVD remains very high
and is expected to increase progressively during the next20 years. The main reasons are the 
progressive increasein the life span and the unsatisfactory control of CV riskfactors in the 
general population at risk for CVD. For all these reasons, CVD prevention, that is, preventing 
or delaying clinical disease among asymptomatic andalready exposed individuals, remains 
an issue of majorpublic health interest.The overall incidence of CVD and its complications
depend on the prevalence and clinical relevance of aseries of major CV risk factors that 
are involved, directlyor indirectly, in the development and progression of atherosclerotic 
disease. Most of these risk factorscoexist in the same subject, and their cumulative effect is
responsible for the development of CV complications.This implies that the overall 
estimation of the presenceand relative weight of established risk factors is a mandatory 
strategy to identify the subjects at risk for CVD whomust be considered as the target of 
an aggressive CVDprevention. In practical terms, any effective approach toprimary care 
or primary prevention of CVDs is built onthe identifi cation of multivariate models that can 
reasonably predict the absolute risk for future CV events inlarge segments of the population. 
However, these risk scores area major advance over clinical risk prediction, and CVD
prevention is certainly one of the few areas in clinicalpractice where such an approach 
is steadily included intopractice guidelines. The concept of “total cardiovascular
risk” has been recently developed as an estimate of theoverall propensity of a subject 
to fall outside the boundaries of average CV risk based on the levels of different risk
factors. Accordingly, most of the currently available risk scores have been developed 
in accordance withthe notion of total CV r isk, which actual ly represents the
theoret ica l  rat ionale behind any effect ive st rategy of  CVr isk management.
Hypertension is never born “resistant”; it canbecome resistant if treatment is initiated 
too latein the course of the continuum of cardiovasculardisease. This continuum
as an arch, the thickness of which progressivelyincreases while the risk of cardiovascular 
eventsprogressively increases by the development ofasymptomatic organ damage fi rst, 
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then the appearance of symptomatic disease, and finally the onsetof cardiovascular 
events. Intervention trialsindicate that antihypertensive treatment is capableof reducing 
outcomes by approximately 25%–30%independent of the risk level at which treatment is
started. This fi nding has usually been translatedinto the concept that the absolute benefi t of 
treatment is greater in high-risk patients, but the othercorollary of this fi nding, namely, that 
the residualrisk is also greater, has been ignored. The existence of a consistent residual 
risk in highrisk patients and the fi nding that some of thesehigh-risk patients may be scarcely 
amenable totreatment benefi ts underline the limitations ofl ate interventions and suggests 
that the recommendations by many private or public health-careproviders, including the 2011 
National Institutefor Health and Clinical Excellence (NICE) inthe United Kingdom, to limit 
interventions inpatients with a total cardiovascular risk above 20%in 10 years may be unwise. 
The alternative recommendations may be “the earlier the better,” butthen the challenge is in 
establishing when early isnot too late but also not excessively early.a combined assessment 
of the number and interaction of CV risk factors is the concept thatallows the defi nition of the 
“global CV risk.” Correct estimation of global CV risk is a crucial step for the identifi cation of 
all the subjects where a preventive treatment iswarranted including those with a borderline 
abnormalityof several CV risk factors who would not have been otherwise treated according 
to a less comprehensive approachto CVD prevention focused on the identification and 
treatment of the prevalent risk factors. In conclusion, the available data suggest that clinicians
who see the patients for the prevention of CVD shouldfocus their practice on 
multivariate models that can predict, with reasonably reliability, the global risk of CV
events in large segments of the population.
